Germline Modification Carries Risk of Major Social Harm
By Marcy Darnovsky,
Nature
| 06. 04. 2008
Your Editorial 'New sources of sex cells' (Nature 452, 913; 2008), on the potential use of pluripotent stem-cell-derived gametes (PSCDGs) for germline genetic modification and enhancement, suggests that the prospect of stem-cell-derived gametes could trigger renewed calls for regulating human biotechnologies. In those discussions we must, as you warn, be wary of impeding basic research. But we must be equally willing to draw lines proscribing socially pernicious applications.
Germline (that is, inheritable) modification is the most socially consequential and ethically dubious application of human biotechnology; its implications have been explored from a wide range of perspectives. Most of these discussions have focused on the social meaning and repercussions of genetic manipulation of the human species, not on the moral status of human embryos. One can strongly support human-embryo research and still oppose germline modification. Conversely, some opponents of abortion rights support germline modification, so long as no embryos are destroyed in the process.
Although there may be scientific and therapeutic benefits from research on PSCDGs, the case for any such benefits from using these cells for human germline modification is...
Related Articles
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...
By David Jensen [cites CGS' Pete Shanks], The California Stem Cell Report | 06.24.2024
Image by NIH Image Gallery from Flickr
The Biopolitical Times reported this month that the California stem cell and gene therapy program “seems to be in serious trouble.”
“On first glance, it may look impressive, with over a thousand patients...